Mutations in components of the pathway were more prevalent in gastric cancers with suppressed SOX2 expression, compared to the group with maintained expression of SOX2, with the difference being significant for ligase RNF43, which showed mutations in 16.3% of cancers with suppressed expression of SOX2 and in 6.2% of cancers with maintained SOX2 expression (Fisher’s exact test with p = 0.03) and, for TCF7L2, which was mutated in 6.5% of cases with suppressed expression of SOX2, and in none of the cases with maintained expression of SOX2 (Fisher’s exact test with p = 0.009, in Figure 2A). This evidence concerns the gene SOX2 and gastric cancer.